Section 1. Overview Information

<table>
<thead>
<tr>
<th>Participating Organization(s)</th>
<th>National Institutes of Health (NIH)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Components of Participating Organizations</td>
<td>National Institute of Neurological Disorders and Stroke (NINDS)</td>
</tr>
<tr>
<td>Other Interested NIH Institutes/Centers</td>
<td>National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) National Center for Complementary &amp; Integrative Health (NCCIH) National Institute of Diabetes and Digestive and Kidney Disease (NIDDK) Office of Research on Women’s Health (ORWH) National Institute on Alcohol Abuse and Alcoholism (NIAAA) National Institute of Dental and Craniofacial Research (NIDCR)</td>
</tr>
<tr>
<td>Research Opportunity Title</td>
<td>HEAL Initiative: EPPIC-Net Pain Research Asset Application (OT1)</td>
</tr>
<tr>
<td>Activity Code</td>
<td>OT1: Pre-Application for an Other Transaction Award</td>
</tr>
<tr>
<td>Research Opportunity Number</td>
<td>OTA-19-008</td>
</tr>
<tr>
<td>Related Notices</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Key Dates:</td>
<td>Posted Date: September 3, 2019 Open Date (Earliest Submission Date): September 3, 2019 Application Due Date(s): Rolling Submission, Deadlines for scheduled review dates will be posted on the EPPIC-Net Website</td>
</tr>
<tr>
<td>Scientific Contacts</td>
<td>Barbara Karp, MD, NINDS EPPIC-Net Director <a href="mailto:barbara.karp@nih.gov">barbara.karp@nih.gov</a></td>
</tr>
</tbody>
</table>

Content by Sections

| Overview Information | 1 |
| Objectives of this opportunity | 2 |
| Potential Award Information | 3 |
| Eligibility | 4 |
| Application Information and Submission | 5 |
| Objective Review Information | 6 |

Section 2. Objectives of this Opportunity

The NIH Helping End Addiction Long-term (HEAL) Initiative seeks to speed scientific solutions to stem the national opioid public health crisis. Opioid overdose deaths reached
more than 42,000 annually in 2016 and more than 2 million Americans are addicted to opioids. There are also 25 million people, or 11% of the U.S. population, who experience daily chronic pain, many of whom are prescribed opioids for pain management. New treatment options for pain are needed to reduce the number of people exposed to the risks of opioids.

There is a clear public health imperative to stimulate and support research that improves the care and outcomes of patients with severe acute and chronic pain. The Federal Pain Research Strategy (https://iprcc.nih.gov/Federal-Pain-Research-Strategy/Overview), published in 2017, identified the development of safer non-opioid analgesics as a top priority and specifically noted the need for the discovery and validation of new pharmacologic and non-pharmacologic targets for the treatment of pain. There is also an urgent need to optimize and validate objective mechanistic biomarkers associated with pain conditions and to better understand the biologic mechanisms that underlie different pain conditions, as well as the mechanisms that tie pain conditions together.

To address this need, as part of the HEAL Initiative, NINDS has established the Early Phase Pain Investigation Clinical Network (EPPIC-Net). EPPIC-Net provides a robust and readily accessible infrastructure for the rapid design and performance of high-quality early phase clinical trials to test promising novel therapeutics for pain submitted by partners in academia or industry that also incorporate in-depth phenotyping and biomarker evaluation. These studies will bring intense focus to patients with well-defined pain conditions and high unmet therapeutic needs.

The purpose of this research opportunity announcement (ROA) is to invite Stage 1 preliminary applications for submission of therapeutics, including but not limited to, drugs, biologics, and devices as well as biomarkers (termed “assets”) for study in the HEAL Initiative’s EPPIC-Net. EPPIC-Net applications will be reviewed in a three-stage process. Applications to Stages 2 & 3 will be by invitation only and will involve more detail than is requested in Stage 1 (see Section 5: Application Information and Submission, for more information).

The ideal therapeutic drug or device “asset” for EPPIC-Net is phase 2-ready with an existing FDA IND or IDE. Pre-clinical data on mechanism of action, target engagement, and safety, including addiction potential should be available. The asset may be proposed to address adult and/or pediatric populations and any pain condition.

EPPIC-Net will use novel, efficient study designs including adaptive and platform designs. It will incorporate validation studies of biomarkers and biomarker-informed proof-of-principle or target engagement studies. EPPIC-Net will make all EPPIC-Net trial data (including clinical, neuroimaging, biomarker, and preclinical data) and biosamples available through public-access data and biospecimen repositories.

**EPPIC-Net Organization**
The EPPIC-Net infrastructure consists of one Clinical Coordinating Center, one Data Coordinating Center, and 12 Specialized Clinical Sites able to coordinate and conduct clinical trials across different pain conditions in a large number of centers across the United States.

The Clinical Coordinating Center (CCC) provides scientific and organizational leadership to EPPIC-Net to achieve both efficiency and excellence in the performance of clinical
trials. The CCC coordinates the EPPIC-Net central IRB, establishes master contract agreements with the Clinical Sites for trial performance, develops recruitment plans, coordinates study staff training, tracks enrollment and oversees quality improvement. The roles and responsibilities of the CCC are described in [RFA-NS-19-023](https://grants.nih.gov/grants/guide/notice-files/NOT-NS-19-023.html).

The Data Coordinating Center (DCC) provides scientific and organizational leadership to EPPIC-Net in all aspects of data management, data quality, statistical design, statistical analysis, and through managing a biosample repository. The DCC supports the Data and Safety Monitoring Board and manages reporting to regulatory authorities (e.g., central IRB, FDA). The role and responsibilities of the DCC are described in [RFA-NS-19-024](https://grants.nih.gov/grants/guide/notice-files/NOT-NS-19-024.html).

The Specialized Clinical Centers provide scientific leadership and conduct the clinical studies. The Specialized Clinical Centers (hubs) are regional academic medical centers that both enroll patients directly and provide organizational leadership to its network of 2-10 satellite “spokes” that also enroll patients. Each hub and its spokes have physicians and investigators with expertise in a wide variety of pain conditions across multiple specialties (e.g., neurology, rheumatology, obstetrics/gynecology, oncology, pediatrics, orthopedics, gastroenterology, and others), and have access to clinical populations with a broad range of pain conditions. EPPIC-Net has the ability to add ad hoc hubs/spokes if needed for particular clinical trials. The roles and responsibilities of the Specialized Clinical Centers are described in [RFA-NS-19-025](https://grants.nih.gov/grants/guide/notice-files/NOT-NS-19-025.html).

Scope
As well as drugs, biologicals, and devices, EPPIC-Net may consider studies of natural products, surgical, and non-pharmacological interventions. EPPIC-Net will also incorporate investigations of biomarker discovery and validation and clinical studies to uncover underlying biologic mechanisms in specific pain conditions with deep phenotyping and clinical characterization.


For purposes of this ROA, NCCIH is interested in applications proposing clinical trials of devices or natural products (e.g. botanicals, dietary supplements, or probiotics) relevant to complementary health interventions for the treatment of any pain condition.

Section 3. Potential Award Information

Please note:
No funding is provided to the asset holders who apply to have their therapeutics studied within EPPIC-Net. After the EPPIC-Net 3 stage application and review process (described below), successful asset holders obtain access to EPPIC-Net, which will develop and conduct clinical trials with accepted assets in cooperation with the asset-owner. NIH Other Transaction funds to conduct the study are awarded to the EPPIC-Net CCC, which
administers the funds to other EPPIC-Net research components.

**Authority:**
This Research Opportunity Announcement (ROA) is issued with the goal of soliciting novel pain therapeutic “assets” to be studied within EPPIC-Net. Assets will be selected through a multi-stage application and review process. Successful application will result the asset being eligible for study and in the establishment an “other transactions award (OTA)” agreement with funds provided to EPPIC-Net Centers and Sites for conduct of the study pursuant to 42 U.S.C. § 285b-3.

**Section 4. Eligibility**

**Organizations**
The following entities are eligible to apply under this ROA:

**Higher Education Institutions**
- Public/State Controlled Institutions of Higher Education
- Private Institutions of Higher Education

The following types of Higher Education Institutions are always encouraged to apply for NIH support as Public or Private Institutions of Higher Education:
- Hispanic-serving Institutions
- Historically Black Colleges and Universities (HBCUs) Tribally Controlled Colleges and Universities (TCCUs) Alaska Native and Native Hawaiian Serving Institutions
- Asian American Native American Pacific Islander Serving Institutions (AANAPISIs)

**Nonprofits Other Than Institutions of Higher Education**
- Nonprofits with 501(c)(3) IRS Status (Other than Institutions of Higher Education)
- Nonprofits without 501(c)(3) IRS Status (Other than Institutions of Higher Education)

**For-Profit Organizations**
- Small Businesses
- For-Profit Organizations (Other than Small Businesses)

**Governments**
- State Governments County Governments
- City or Township Governments Special District Governments
- Indian/Native American Tribal Governments (Federally Recognized)
- Indian/Native American Tribal Governments (Other than Federally Recognized)
- Eligible Agencies of the Federal Government
- U.S. Territory or Possession Independent School Districts

**Other**
- Independent School Districts
- Public Housing Authorities/Indian Housing Authorities
- Native American Tribal Organizations (other than Federally recognized tribal governments)

**Faith-based or Community-based Organizations**
- Regional Organizations
- Non-domestic (non-U.S.) Entities (Foreign Institutions)
**Foreign Institutions**

- Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply.
- Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.

**Eligible Individuals (Program Director/Principal Investigator):** Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an asset application. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.

**Section 5. Application Information and Submission**

**Application Process Overview**

Academic, industry and other investigators may submit an application to have their therapeutic candidate “asset” (e.g., novel drug, biologic, and devices) studied within EPPIC-Net.

There are 3 stages of application and review:

**Stage 1 Preliminary application:** The EPPIC-Net preliminary application packet is available at: https://www.ninds.nih.gov/Current-Research/Trans-Agency-Activities/NINDS-Role-HEAL-Initiative/NINDS-Role-HEAL-Initiative-EPPIC. The preliminary applications requests summary/overview information on the proposed asset and associated clinical trial. Preliminary applications will be submitted in response to this Stage 1 Research Opportunity Announcement (ROA). The Stage 1 applications will be received and reviewed on a rolling basis with intermediate pre-determined review cut-off dates. These preliminary applications will be objectively reviewed by a panel of external experts convened by NIH. See below for information on the review process.

**Stage 2 Dossier application:** Asset applicants with high ranking preliminary applications will be selected to work with an NIH contractor to prepare a “dossier” with detailed information on the asset, including prior basic, pre-clinical and clinical research completed as well as information on the study population, design, and rationale. Dossiers will be submitted under a separate Stage 2 OTA ROA. The Stage 2 applications will be received and reviewed on a rolling basis with intermediate pre-determined review cut-off dates. The Stage 2 applications will be objectively reviewed by a panel of external experts convened by NIH, including individuals who reviewed the preliminary applications along with additional experts as needed.

**Stage 3 Protocol application:** Asset applicants with top-ranking dossiers will be selected to proceed to work with the EPPIC-Net to develop the study-specific clinical protocols. Specifically, within 90 days of dossier approval, the EPPIC-Net CCC and DCC, together with the applicant and experts selected from the Clinical Sites, will produce a detailed clinical trial protocol for the asset, a budget, and a
timeline that will then be submitted under the Stage 3 OTA ROA. If appropriate, the application could include a proposal for additional clinical sites from outside the network. The final protocol, budget, and timeline will make up the Stage 3 (OTA) application which will then be reviewed by the external objective review panel, including potential additional experts if required. Top-ranking protocols will be presented to the NINDS Council and HEAL Leadership, who will approve meritorious protocols for funding and study implementation within EPPIC-Net.

NIH HEAL and NINDS Approval
The final decision and approval for an Other Transaction Award (OTA) and to execute the protocol will come from the NIH HEAL Executive Committee and will include consideration by the HEAL Multi-disciplinary Working Group and approval of the NINDS Council. A Notice of Award will be provided.

After NIH HEAL Executive Committee and NINDS Council approval, OTA trial funds will be released to EPPIC-Net CCC and the clinical trial may begin.

Important Reminder: there is no funding associated with this specific research opportunity announcement. NIH Other Transaction funds to conduct the study are awarded to the EPPIC-Net CCC for conduct of the trial only after successful completion of all 3 stages of application and review.

Submission Information

Section 6. Objective Review Information
Assets to be studied within EPPIC-Net will be selected through an objective review process. It is anticipated that there will be multiple concurrent asset clinical trials.

Objective review is an assessment of scientific or technical merit of applications by individuals with appropriate scientific knowledge and peer expertise. Objective review is essential to ensuring selection of applications that best meet the needs of the program using established criteria (further outlined below) and providing assurance to the public that the evaluation and selection process was impartial and fair. To achieve this result, NIH will conduct reviews using standard practices that follow ethical standards applied to all extramural research. The review process should be viewed by practitioners, participants, and the public as credible and fair. Conflicts of interest, prejudices, biases, or predispositions will be appropriately managed during the review process.

Reviewers will individually provide an assessment of the likelihood for the asset submitted to exert a sustained, powerful influence on the management of acute and chronic pain.

Objective Review Criteria:
Significance
• Do the asset and approach appropriately target a specific type of pain with high unmet therapeutic need?
• Do the asset and approach represent a marked improvement over existing pain therapies?
• Will the asset and proposed study notably advance the field of pain therapy?

Approach
• Is testing this asset in a Phase 2 Clinical Trial realistic?
• Will the asset be scalable?
• Is sufficient asset available for a Phase 2 Clinical Trial, and if not, are well-defined plans in place for producing an adequate supply of the asset?
• Will the asset be scalable for eventual clinical use?
• Is there a reasonably rapid timeline for bringing this asset to a clinical trial?
• Are novel methods, assays, or approaches proposed?
• Are safety and biohazard considerations for use of the asset in humans clearly addressed

Viability/Feasibility
• Is the asset appropriate for the proposed indication?
• Does the study information provided, support a Phase 2 Clinical Trial?
• Is there a path forward for eventual clinical adoption?
• Are there barriers to use of the asset in the proposed study or eventually in the clinic? Have safety and regulatory IND/IDE studies been completed, indicating readiness for a Phase 2 Clinical Trial?

Composition of Objective Review Panel

From an established panel of expert reviewers, a sub-set will be used for each objective review meeting depending on the expertise needed. Additional ad hoc members will be added as necessary to cover specific areas of science not included in the main panel. The review of the EPPIC-Net preliminary applications will be carried out by experts with knowledge of multiple areas of science such as pharmacokinetics, biological mechanisms, pharmaceutical industry development, and relevant scientific and clinical expertise. Review rosters will be made publicly available on the EPPIC-Net website prior to deliberation. Review panel member conflicts-of-interest will be guided by current NIH policy and practice. NIH program officials will attend the reviews to provide programmatic input. Standard summary statements of review panel meetings will not be produced. However, decision feedback will be provided to applicants. Appeals will not be allowed.